^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    RANK ligand inhibitor

    Related drugs:
    1d
    The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy. (PubMed, J Genet Genomics)
    CSF1R inhibitor can inhibit the tumor growth of recurrent GCTB. Targeting CSF1R and alleviating T cell exhaustion may provide therapeutic insights for the management of relapsed GCTB following DMAb discontinuation.
    Journal
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • TNFSF11 (TNF Superfamily Member 11)
    |
    Prolia (denosumab)
    8d
    Romosozumab/Denosumab Study for Premenopausal IOP (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Columbia University | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Prolia (denosumab)
    8d
    Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A. (PubMed, Biomedicines)
    The targeted inhibition of osteoclast activity with denosumab has transformed clinical management, inducing profound morphological changes and bone formation...Collectively, GCTB exemplifies a molecularly defined bone tumor in which advances in epigenetic biology and tumor-microenvironment interactions have directly influenced diagnostic practice and therapeutic strategy. Ongoing challenges include refining risk stratification, optimizing treatment sequencing, and clarifying the biological consequences of sustained osteoclast suppression.
    Review • Journal
    |
    H3-3A (H3.3 Histone A)
    |
    Prolia (denosumab)
    16d
    Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis. (PubMed, J Oncol Pharm Pract)
    She received ribociclib with a reduced dose due to haematological toxicity, as well as letrozole and denosumab due to bone metastasis. Ribociclib was administered safely and effectively for nine months.DiscussionWe presented our experience of using ribociclib in a patient with metastatic breast cancer who was receiving hemodialysis. Ribociclib was administered safely, and a response to the treatment was achieved.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Kisqali (ribociclib) • letrozole • Prolia (denosumab)
    23d
    Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China (clinicaltrials.gov)
    P4, N=102, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Prolia (denosumab)
    23d
    The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (clinicaltrials.gov)
    P4, N=52, Not yet recruiting, National Taiwan University Hospital
    New P4 trial • Head-to-Head
    |
    Prolia (denosumab) • zoledronic acid • ibandronate sodium hydrate
    25d
    A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® (clinicaltrials.gov)
    P3, N=504, Completed, Enzene Biosciences Ltd. | Recruiting --> Completed
    Trial completion
    |
    Prolia (denosumab)
    29d
    The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=27, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    1m
    Comparison of the Efficacy of Teriparatide Injection Combined with Denosumab Injection Versus Denosumab Injection Alone in Patients with Osteoporosis (ChiCTR2600117736)
    P=N/A, N=200, Not yet recruiting, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University; West China Hospital, SCU
    New trial
    |
    Prolia (denosumab)
    1m
    Denosumab improves periprosthetic bone mineral density and bone strength after primary total hip arthroplasty by regulating the expression of bone type I collagen (ChiCTR2500112683)
    P=N/A, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    Prolia (denosumab)
    1m
    The efficacy of denosumab vs zoledronic acid in surgical/non-surgical treatment of patients with osteoporotic thoracolumbar fractures: a prospective, multicenter, randomized, double-blind, controlled study (ChiCTR2500112918)
    P=N/A, N=188, Recruiting, Hebei Medical University Third Hospital; Hebei Medical University Third Hospital
    New trial
    |
    Prolia (denosumab) • zoledronic acid
    1m
    A prospective, multicenter, observational study evaluating the efficacy and safety of denosumab (Luxan®) in preventing knee prosthesis displacement in postmenopausal patients with osteoporosis after total knee arthroplasty (ChiCTR2500113856)
    P4, N=250, Not yet recruiting, The First Affiliated Hospital of Chongqing Medical University; No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing
    New P4 trial
    |
    Prolia (denosumab)